Cellect Biotechnology Ltd. (APOP)
Stock Price:
$1.78 USD
0.08 (4.53%)
Updated Oct 29, 2020 1:27 PM EDT - Market open
Key Info
| Market Cap |
6.95M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-16.81M |
| Shares Out |
3.91M |
| EPS (ttm) |
-0.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$1.78 |
| Previous Close |
$1.70 |
| Change ($) |
0.08 |
| Change (%) |
4.53% |
| Day's Open |
1.90 |
| Day's Range |
1.74 - 2.05 |
| Day's Volume |
5,059,443 |
| 52-Week Range |
0.40 - 6.89 |
More Stats
| Market Cap |
6.95M |
| Enterprise Value |
2.08M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
3.91M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.85 |
| FCF / Share |
-0.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
91,185 |
| Short Ratio |
0.48 |
| Short % of Float |
n/a |
| Beta |
2.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.33 |
| Revenue |
n/a |
| Operating Income |
-6.38M |
| Net Income |
-16.81M |
| Free Cash Flow |
-5.84M |
| Net Cash |
4.87M |
| Net Cash / Share |
1.25 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-37.82% |
| ROE |
-101.81% |
| ROIC |
2,165.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: $1.78
High
3.00
Target: 3.00
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions ILS.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -22.33 | -29.25 | -24.43 | -15.94 | -10.10 | -5.55 | -3.49 |
| Net Income | -16.81 | -20.11 | -28.22 | -15.32 | -10.17 | -5.55 | -3.68 |
| Shares Outstanding | 213 | 129 | 112 | 18.23 | 14.90 | 13.19 | 9.83 |
| Earnings Per Share | -0.08 | -0.16 | -0.25 | -0.84 | -0.69 | -0.42 | -0.38 |
| Operating Cash Flow | -20.34 | -23.64 | -17.77 | -14.41 | -7.71 | -4.40 | -2.63 |
| Capital Expenditures | -0.12 | -0.66 | -0.27 | -1.17 | -0.26 | -0.23 | -0.02 |
| Free Cash Flow | -20.45 | -24.29 | -18.04 | -15.58 | -7.97 | -4.63 | -2.65 |
| Cash & Equivalents | 18.11 | 17.81 | 27.73 | 30.94 | 11.74 | 13.38 | - |
| Total Debt | 1.07 | - | - | - | - | - | - |
| Net Cash / Debt | 17.03 | 17.81 | 27.73 | 30.94 | 11.74 | 13.38 | - |
| Assets | 21.32 | 20.64 | 30.37 | 33.91 | 13.36 | 13.79 | - |
| Liabilities | 6.48 | 6.72 | 11.52 | 5.42 | 2.86 | 0.84 | - |
| Book Value | 14.84 | 13.92 | 18.85 | 28.49 | 10.50 | 12.96 | - |
Numbers in millions ILS, except per-share numbers.
Company Details
| Full Name |
Cellect Biotechnology Ltd. |
| Country |
Israel |
| Employees |
14 |
| CEO |
Shai Yarkoni |
Stock Information
| Ticker Symbol |
APOP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: APOP |
Description
Cellect Biotechnology, a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.